Clinical Research Papers:

Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients’ selection of transcatheter arterial chemoembolization and sorafenib

Sirui Fu, Shuting Chen, Changhong Liang, Zaiyi Liu, Yanjie Zhu, Yong Li and Ligong Lu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:37855-37865. https://doi.org/10.18632/oncotarget.13675

Metrics: PDF 1643 views  |   HTML 2038 views  |   ?  


Sirui Fu1, Shuting Chen2,3, Changhong Liang3, Zaiyi Liu3, Yanjie Zhu4, Yong Li1, Ligong Lu1

1Department of Interventional Oncology, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

2Southern Medical University, Guangzhou, China

3Department of Radiology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

4Shenzhen Institutes of Advanced Technology, Shenzhen, China

Correspondence to:

Ligong Lu, email: [email protected]

Keywords: hepatocellular carcinoma, texture analysis, sorafenib, transcatheter arterial chemoembolization

Received: July 20, 2016     Accepted: November 14, 2016     Published: November 29, 2016


Transcatheter arterial chemoembolization (TACE) and sorafenib combination treatment for unselected hepatocellular carcinoma (HCC) is controversial. We explored the potential of texture analysis for appropriate patient selection. There were 261 HCCs included (TACE group: n = 197; TACE plus sorafenib (TACE+Sorafenib) group n = 64). We applied a Gabor filter and wavelet transform with 3 band-width responses (filter 0, 1.0, and 1.5) to portal-phase computed tomography (CT) images of the TACE group. Twenty-one textural parameters per filter were extracted from the region of interests delineated around tumor outline. After testing survival correlations, the TACE group was subdivided according to parameter thresholds in receiver operating characteristic curves and compared to TACE+Sorafenib group survival. The Gabor-1-90 (filter 0) was most significantly correlated with TTP. The TACE group was accordingly divided into the TACE-1 (Gabor-1-90 ≤ 3.6190) and TACE-2 (Gabor-1-90 > 3.6190) subgroups; TTP was similar in the TACE-1 subgroup and TACE+Sorafenib group, but shorter in the TACE-2 subgroup. Only wavelet-3-D (filter 1.0) correlated with overall survival (OS), and was used for subgrouping. The TACE-5 (wavelet-3-D ≤ 12.2620) subgroup and the TACE+Sorafenib group showed similar OS, while the TACE-6 (wavelet-3-D > 12.2620) subgroup had shorter OS. Gabor-1-90 and wavelet-3-D were consistent.Independent of tumor number or size, CT textural parameters are correlated with TTP and OS. Patients with lower Gabor-1-90 (filter 0) and wavelet-3-D (filter 1.0) should be treated with TACE and sorafenib. Texture analysis holds promise for appropriate selection of HCCs for this combination therapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13675